A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. However, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking. Moreover, it remains unknown whether vaccination can augment such responses. We found that a dendritic cell vaccine led to an increase in naturally occurring neoantigen-specific immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma. The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in terms of both TCR-β usage and clonal composition. Our results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vaccines have been used as an approach to enhance anti-tumor immune responses and have demonstrated encouraging results in preclinical and clinical studies, leading to an expansion of the intratumoral T cell infiltration and anti-tumor immune responses (Carreno et al., 2015; Ott et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Carreno et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1196 · Cited by 1,214
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,074
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cited by
Items 101–200 of 1,003
Developing neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 238
Immunotherapy for Breast Cancer: What Are We Missing?
Vonderheide, R. H., Domchek, S. M., & Clark, A. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2569 · Cited by 233
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 232
An RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 229
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 228
Immune targets and neoantigens for cancer immunotherapy and precision medicine
Wang, R.-F., & Wang, H. Y. (2017) · Cell Research · doi:10.1038/cr.2016.155 · Cited by 225
Cancer immunotherapy targeting neoantigens
Lu, Y.-C., & Robbins, P. F. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.002 · Cited by 223
Cancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 217
Vaccine Therapies for Cancer: Then and Now
Morse, M. A., Gwin, W. R., & Mitchell, D. A. (2021) · Targeted Oncology · doi:10.1007/s11523-020-00788-w · Cited by 215
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 215
Best practices for bioinformatic characterization of neoantigens for clinical utility
Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 214
Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*
Caron, E., Kowalewski, D., Chiek Koh, C., Sturm, T., Schuster, H., & Aebersold, R. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o115.052431 · Cited by 213
Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Efremova, M., Finotello, F., Rieder, D., & Trajanoski, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01679 · Cited by 211
Current Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 210
Engineering patient-specific cancer immunotherapies
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208
Briseño, C. G., Haldar, M., Kretzer, N. M., Wu, X., Theisen, D. J., KC, W., Durai, V., Grajales-Reyes, G. E., Iwata, A., Bagadia, P., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.025 · Cited by 208
Mastering variation: Variance components and personalised medicine
Senn, S. (2016) · Statistics in Medicine · doi:10.1002/sim.6739 · Cited by 205
“For example, suppose that the treatment itself is derived from the patient’s own cells as a sort of personalised vaccine [29].”
BackgroundTrolle, T., McMurtrey, C. P., Sidney, J., Bardet, W., Osborn, S. C., Kaever, T., Sette, A., Hildebrand, W. H., Nielsen, M., & Peters, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501721 · Cited by 205
Self-citationTricking the balance: NK cells in anti-cancer immunity
Pahl, J., & Cerwenka, A. (2017) · Immunobiology · doi:10.1016/j.imbio.2015.07.012 · Cited by 205
Applications of Immunogenomics to Cancer
Liu, X. S., & Mardis, E. R. (2017) · Cell · doi:10.1016/j.cell.2017.01.014 · Cited by 205
Self-citationEngineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0400-z · Cited by 203
Masucci, G. V., Cesano, A., Hawtin, R., Janetzki, S., Zhang, J., Kirsch, I., Dobbin, K. K., Alvarez, J., Robbins, P. B., Selvan, S. R., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0178-1 · Cited by 202
High-throughput determination of the antigen specificities of T cell receptors in single cells
Zhang, S.-Q., Ma, K.-Y., Schonnesen, A. A., Zhang, M., He, C., Sun, E., Williams, C. M., Jia, W., & Jiang, N. (2018) · Nature Biotechnology · doi:10.1038/nbt.4282 · Cited by 200
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
van der Lee, D. I., Reijmers, R. M., Honders, M. W., Hagedoorn, R. S., de Jong, R. C. M., Kester, M. G. D., van der Steen, D. M., de Ru, A. H., Kweekel, C., Bijen, H. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97482 · Cited by 200
High-throughput determination of the antigen specificities of T cell receptors in single cells
Zhang, S.-Q., Ma, K.-Y., Schonnesen, A. A., Zhang, M., He, C., Sun, E., Williams, C. M., Jia, W., & Jiang, N. (2018) · doi:10.1101/457069 · Cited by 199
Chong, C., Marino, F., Pak, H., Racle, J., Daniel, R. T., Müller, M., Gfeller, D., Coukos, G., & Bassani-Sternberg, M. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir117.000383 · Cited by 197
The Human Vaccines Project: A roadmap for cancer vaccine development
Romero, P., Banchereau, J., Bhardwaj, N., Cockett, M., Disis, M. L., Dranoff, G., Gilboa, E., Hammond, S. A., Hershberg, R., Korman, A. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf0685 · Cited by 194
Vaccines targeting helper T cells for cancer immunotherapy
Melssen, M., & Slingluff, C. L. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.004 · Cited by 192
Personalized Dendritic Cell Vaccines‐Recent Breakthroughs and Encouraging Clinical Results
Mastelic-Gavillet, B., Balint, K., Boudousquie, C., Gannon, P. O., & Kandalaft, L. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00766 · Cited by 189
Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination
Persano, S., Guevara, M. L., Li, Z., Mai, J., Ferrari, M., Pompa, P. P., & Shen, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.019 · Cited by 187
Clinical and immunological effects of mRNA vaccines in malignant diseases
Heine, A., Juranek, S., & Brossart, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01339-1 · Cited by 181
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
Bol, K. F., Schreibelt, G., Rabold, K., Wculek, S. K., Schwarze, J. K., Dzionek, A., Teijeira, A., Kandalaft, L. E., Romero, P., Coukos, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0580-6 · Cited by 179
Tumor immune microenvironment in head and neck cancers
Chen, S. M. Y., Krinsky, A. L., Woolaver, R. A., Wang, X., Chen, Z., & Wang, J. H. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23162 · Cited by 179
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Garofalo, A., Sholl, L., Reardon, B., Taylor-Weiner, A., Amin-Mansour, A., Miao, D., Liu, D., Oliver, N., MacConaill, L., Ducar, M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0333-9 · Cited by 179
Delivery strategies of cancer immunotherapy: recent advances and future perspectives
Zhao, Z., Zheng, L., Chen, W., Weng, W., Song, J., & Ji, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0817-3 · Cited by 177
Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
Fucikova, J., Palova-Jelinkova, L., Bartunkova, J., & Spisek, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02393 · Cited by 173
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Himes, B. T., Geiger, P. A., Ayasoufi, K., Bhargav, A. G., Brown, D. A., & Parney, I. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.770561 · Cited by 170
Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses
Clausen, B. E., & Stoitzner, P. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00534 · Cited by 170
Predicting Antigen Presentation—What Could We Learn From a Million Peptides?
Gfeller, D., & Bassani-Sternberg, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01716 · Cited by 170
Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
Kosmides, A. K., Sidhom, J.-W., Fraser, A., Bessell, C. A., & Schneck, J. P. (2017) · ACS Nano · doi:10.1021/acsnano.6b08152 · Cited by 170
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Morishita, Y., Kashiwabara, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.005 · Cited by 167
Antigen Dominance Hierarchies Shape TCF1+ Progenitor CD8 T Cell Phenotypes in Tumors
Burger, M. L., Cruz, A. M., Crossland, G. E., Gaglia, G., Ritch, C. C., Blatt, S. E., Bhutkar, A. J., Canner, D. A., Kienka, T., Tavana, S. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.020 · Cited by 167
Dendritic Cells in Cancer Immunology and Immunotherapy
Hato, L., Atienza, Á. V., Eguren‐Santamaría, I., Perez‐Gracia, J. L., Rodríguez, J., Pérez‐Larraya, J. G., Sarobe, P., Inogés, S., de Cerio, A. L. D., & Santisteban, M. (2024) · Cancers · doi:10.3390/cancers16050981 · Cited by 167
Kinkead, H. L., Hopkins, A., Lutz, E., Wu, A. A., Yarchoan, M., Cruz, K., Woolman, S., Vithayathil, T., Glickman, L. H., Ndubaku, C. O., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122857 · Cited by 166
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
Guo, Y., Lei, K., & Tang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01499 · Cited by 166
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
De Keersmaecker, B., Claerhout, S., Carrasco, J., Bar, I., Corthals, J., Wilgenhof, S., Neyns, B., & Thielemans, K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000329 · Cited by 165
Banchereau, J., & Palucka, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.149 · Cited by 166
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
Landscape of Tumor Antigens in T Cell Immunotherapy
Ilyas, S., & Yang, J. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501657 · Cited by 163
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C.-H., Yelensky, R., Jooss, K., & Chan, T. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 162
Seo, H., Jeon, I., Kim, B.-S., Park, M., Bae, E.-A., Song, B., Koh, C.-H., Shin, K.-S., Kim, I.-K., Choi, K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15776 · Cited by 161
Erratum: Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.74 · Cited by 160
Qin, L., Cao, J., Shao, K., Tong, F., Yang, Z., Lei, T., Wang, Y., Hu, C., Umeshappa, C. S., Gao, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb3116 · Cited by 159
Kim, S., Kim, H. S., Kim, E., Lee, M. G., Shin, E.-C., Paik, S., & Kim, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy022 · Cited by 158
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
Wang, Q.-T., Nie, Y., Sun, S.-N., Lin, T., Han, R.-J., Jiang, J., Li, Z., Li, J.-Q., Xiao, Y.-P., Fan, Y.-Y., et al. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02496-w · Cited by 158
De Mattos-Arruda, L., Vazquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 157
Self-citationIntrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
Zhao, X., & Subramanian, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2379 · Cited by 157
Personalized immunotherapy in cancer precision medicine
Kiyotani, K., Toyoshima, Y., & Nakamura, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0032 · Cited by 154
Challenges in neoantigen-directed therapeutics
Lybaert, L., Lefever, S., Fant, B., Smits, E., De Geest, B., Breckpot, K., Dirix, L., Feldman, S. A., van Criekinge, W., Thielemans, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 142
Wang, J., Zhu, M., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113974 · Cited by 153
Richman, L. P., Vonderheide, R. H., & Rech, A. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.08.009 · Cited by 152
Determinants for Neoantigen Identification
Garcia-Garijo, A., Fajardo, C. A., & Gros, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01392 · Cited by 137
Directing Traffic: How to Effectively Drive T Cells into Tumors
Anandappa, A. J., Wu, C. J., & Ott, P. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0790 · Cited by 152
Gupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 152
Hou, B., Zhou, L., Wang, H., Saeed, M., Wang, D., Xu, Z., Li, Y., & Yu, H. (2020) · Advanced Materials · doi:10.1002/adma.201907210 · Cited by 151
Rodríguez-Ruiz, M. E., Perez-Gracia, J. L., Rodríguez, I., Alfaro, C., Oñate, C., Pérez, G., Gil-Bazo, I., Benito, A., Inogés, S., López-Diaz de Cerio, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy089 · Cited by 145
Kristensen, N. P., Heeke, C., Tvingsholm, S. A., Borch, A., Draghi, A., Crowther, M. D., Carri, I., Munk, K. K., Holm, J. S., Bjerregaard, A.-M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150535 · Cited by 150
Mass spectrometry-based antigen discovery for cancer immunotherapy
Bassani‐Sternberg, M., & Coukos, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.04.005 · Cited by 148
Mehrotra, S., Britten, C. D., Chin, S., Garrett-Mayer, E., Cloud, C. A., Li, M., Scurti, G., Salem, M. L., Nelson, M. H., Thomas, M. B., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0459-2 · Cited by 138
Dongye, Z., Li, J., & Wu, Y. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01876-6 · Cited by 149
The landscape of T cell antigens for cancer immunotherapy
Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 147
DC-Based Vaccines for Cancer Immunotherapy
Fu, C., Zhou, L., Mi, Q.-S., & Jiang, A. (2020) · Vaccines · doi:10.3390/vaccines8040706 · Cited by 146
Ge, R., Liu, C., Zhang, X., Wang, W., Li, B., Liu, J., Liu, Y., Sun, H., Zhang, D., Hou, Y., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b05876 · Cited by 146
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Lopez, J. S., Powles, T. B., Braiteh, F., Siu, L. L., LoRusso, P. M., Friedman, C. F., Balmanoukian, A. S., Gordon, M. S., Yachnin, J., Rottey, S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03334-7 · Cited by 145
Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response
Barczak, W., Carr, S. M., Liu, G., Munro, S., Nicastri, A., Lee, L. N., Hutchings, C. L., Ternette, N., Klenerman, P., Kanapin, A. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36826-0 · Cited by 144
Dammeijer, F., Lievense, L. A., Kaijen-Lambers, M. E., van Nimwegen, M., Bezemer, K., Hegmans, J. P., van Hall, T., Hendriks, R. W., & Aerts, J. G. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0309 · Cited by 142
Zhao, H., Xu, J., Feng, C., Ren, J., Bao, L., Zhao, Y., Tao, W., Zhao, Y., & Yang, X. (2022) · Advanced Materials · doi:10.1002/adma.202106390 · Cited by 142
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
Türeci, Ö., Vormehr, M., Diken, M., Kreiter, S., Huber, C., & Sahin, U. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1509 · Cited by 141
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120803 · Cited by 141
The present status and future prospects of peptide-based cancer vaccines
Hirayama, M., & Nishimura, Y. (2016) · International Immunology · doi:10.1093/intimm/dxw027 · Cited by 136
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00508 · Cited by 135
Fang, L., Zhao, Z., Wang, J., Zhang, P., Ding, Y., Jiang, Y., Wang, D., & Li, Y. (2020) · Science Advances · doi:10.1126/sciadv.aba4024 · Cited by 135
Informing immunotherapy with multi-omics driven machine learning
Li, Y., Xin, W., Fang, D., & Luo, Y. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01043-6 · Cited by 135
Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Harding, J. J., El Dika, I., & Abou‐Alfa, G. K. (2016) · Cancer · doi:10.1002/cncr.29769 · Cited by 124
Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens
Pan, R., Chung, W., Chu, M.-T., Chen, S.-J., Chen, H.-C., Zheng, L., & Chung, W. (2018) · Journal of Immunology Research · doi:10.1155/2018/4325874 · Cited by 132
Cancer vaccines: current status and future directions
Zhou, Y., Wei, Y., Tian, X., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01670-w · Cited by 135
The role of neoantigen in immune checkpoint blockade therapy
Yi, M., Qin, S., Zhao, W., Yu, S., Chu, Q., & Wu, K. (2018) · Experimental Hematology & Oncology · doi:10.1186/s40164-018-0120-y · Cited by 131
Towards superior dendritic-cell vaccines for cancer therapy
Saxena, M., Balan, S., Roudko, V., & Bhardwaj, N. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0250-x · Cited by 131
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Ferritin nanoparticle-based SpyTag/SpyCatcher-enabled click vaccine for tumor immunotherapy
Wang, W., Liu, Z., Zhou, X., Guo, Z., Zhang, J., Zhu, P., Yao, S., & Zhu, M. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.11.009 · Cited by 130
Turning tumors from cold to inflamed to improve immunotherapy response
Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 131
Targeting Innate Immunity in Cancer Therapy
Rameshbabu, S., Labadie, B. W., Argulian, A., & Patnaik, A. (2021) · Vaccines · doi:10.3390/vaccines9020138 · Cited by 129
Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Sathyanarayanan, V., & Neelapu, S. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.009 · Cited by 126
Advances in Therapeutic Cancer Vaccines
Wong, K. K. W., Li, A. W., Mooney, D. J., & Dranoff, G. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.001 · Cited by 127
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy
Mandal, R., & Chan, T. A.-T. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0146 · Cited by 128
Neoantigen prediction and the need for validation
Vitiello, A., & Zanetti, M. (2017) · Nature Biotechnology · doi:10.1038/nbt.3932 · Cited by 126
Mysore, V., Cullere, X., Mears, J., Rosetti, F., Okubo, K., Liew, P. X., Zhang, F., Madera-Salcedo, I., Rosenbauer, F., Stone, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24591-x · Cited by 125
Development, Diversity, and Function of Dendritic Cells in Mouse and Human
Anderson, D. A., MURPHY, K. M. M., & Briseño, C. G. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028613 · Cited by 125
Metadata
- Authors
- Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P.
- Affiliations
- Washington University in St. Louis (US)
- Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- University of Oklahoma Health Sciences Center (US)
- MilliporeSigma (United States) (US)
- Corresponding author
- Carreno, Beatriz M.
- ORCID
- Venue
- Science
- Published
- 2015-05-15
- Volume
- 348
- Issue
- 6236
- Pages
- 803-808
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4549796
- OpenAlex
- W2007026865
- Cited by
- 1,285
- References
- 37
- Citations by year
- 2026: 45 · 2025: 90 · 2024: 104 · 2023: 108 · 2022: 126 · 2021: 159 · 2020: 135 · 2019: 138 · 2018: 124 · 2017: 118 · 2016: 99 · 2015: 38
- FWCI
- 62.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (5U54HG00307)
- National Cancer Institute (P30 CA91842, R21 CA179695)
- Barnes-Jewish Hospital Foundation
- Siteman Cancer Frontier Fund
- Our Mark on Melanoma (MOM) Foundation
- Come Out Swinging (COS) Foundation
- Blackout Melanoma Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- dendritic cell vaccine, melanoma, neoantigens, missense mutations, T cell receptor repertoire, HLA-A*0201, T cell-mediated antitumor immunity, clonal diversity, cancer immunotherapy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Melanoma, Mutation, Skin Neoplasms, T-Lymphocytes, Monitoring, Immunologic, HLA-A2 Antigen, Immunotherapy, Active, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Cancer Vaccines, Amino Acid Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.